A government advisory panel in a split vote on June 26 advised the Centers for Disease Control and Prevention to recommend an antibody against respiratory syncytial virus (RSV) for many infants younger than 8 months of age.
In the first vote from the Advisory Committee on Immunization Practices (ACIP) since it was remade by Health Secretary Robert F. Kennedy Jr., a majority of members said they favor making an antibody made by Merck called clesrovimab available to all infants, regardless of underlying health.
